RMTI Stock Overview
Operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$5.15 |
| 52 Week Low | US$1.16 |
| Beta | 1.38 |
| 1 Month Change | 5.29% |
| 3 Month Change | -37.25% |
| 1 Year Change | 51.03% |
| 3 Year Change | -51.67% |
| 5 Year Change | -92.76% |
| Change since IPO | -96.12% |
Recent News & Updates
Recent updates
Rockwell Medical (NASDAQ:RMTI) Might Have The Makings Of A Multi-Bagger
Jan 06
Rockwell Medical, Inc.'s (NASDAQ:RMTI) 28% Dip In Price Shows Sentiment Is Matching Revenues
Nov 15Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Trimmed Their Revenue Forecasts By 15%
Nov 14The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More
Sep 29Rockwell Medical: The Turnaround Is Looking Real
Sep 15Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Aug 11Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity
Jul 12Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?
May 08Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?
Feb 06Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares
Dec 25Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?
Oct 11Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?
Jun 02Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?
Oct 25An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued
Sep 02Rockwell Medical Q2 Earnings Preview
Aug 12Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile
Mar 02Shareholder Returns
| RMTI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.5% | 3.9% | 3.1% |
| 1Y | 51.0% | 12.0% | 23.7% |
Return vs Industry: RMTI exceeded the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: RMTI exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| RMTI volatility | |
|---|---|
| RMTI Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RMTI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RMTI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 237 | Mark Strobeck | www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
Rockwell Medical, Inc. Fundamentals Summary
| RMTI fundamental statistics | |
|---|---|
| Market cap | US$68.52m |
| Earnings (TTM) | -US$1.43m |
| Revenue (TTM) | US$98.92m |
0.7x
P/S Ratio-49.6x
P/E RatioIs RMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMTI income statement (TTM) | |
|---|---|
| Revenue | US$98.92m |
| Cost of Revenue | US$82.19m |
| Gross Profit | US$16.72m |
| Other Expenses | US$18.15m |
| Earnings | -US$1.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 16.91% |
| Net Profit Margin | -1.44% |
| Debt/Equity Ratio | 30.4% |
How did RMTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 22:36 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rockwell Medical, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Ritu Baral | Canaccord Genuity |